argenx to Present at BofA Securities 2025 Health Care Conference

Rhea-AI Summary

argenx (ARGX), a global immunology company focused on severe autoimmune diseases, has announced its participation in the BofA Securities 2025 Health Care Conference. CEO Tim Van Hauwermeiren and other management team members will deliver a presentation on Tuesday, May 13, 2025, at 4:20 p.m. PT.

The presentation will be accessible through a live webcast on the Investors section of argenx's website at argenx.com/investors. A replay will remain available for approximately 30 days after the event.

[]

News Market Reaction – ARGX

-6.33%

-6.33% Session move

In the trading session that priced this news, ARGX declined 6.33%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

May 6, 2025

Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Tim Van Hauwermeiren, Chief Executive Officer, and members of the management team will present at the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025 at 4:20 p.m. PT.

A live webcast of the presentation may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately 30 days following the presentation.

About argenx

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, Instagram, Facebook, and YouTube.

Contacts

Media:

Ben Petok
bpetok@argenx.com

Investors:

Alexandra Roy
aroy@argenx.com

FAQ

When is ARGX presenting at the BofA Securities 2025 Health Care Conference?

argenx (ARGX) is presenting on Tuesday, May 13, 2025 at 4:20 p.m. PT at the BofA Securities 2025 Health Care Conference.

Who will be presenting for ARGX at the BofA Securities healthcare conference?

Tim Van Hauwermeiren, CEO of argenx, along with members of the management team will be presenting at the conference.

How can investors access ARGX's BofA Securities conference presentation?

Investors can access the live webcast through the Investors section of argenx's website at argenx.com/investors. A replay will be available for approximately 30 days after the presentation.

What does argenx (ARGX) company specialize in?

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases.